Non-small Cell Carcinoma: Clinical Trials

8 trials for Non-small Cell Carcinoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

2 completed, 2 terminated, 1 active not recruiting, 1 recruiting. 8 Phase 2, 2 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 2, Terminated 2, Active not recruiting 1, Recruiting 1, Unknown 1, Withdrawn 1
Phase 12Completed 1, Unknown 1

Follow Non-small Cell Carcinoma: new trials by email Literature Review of Non-small Cell Carcinoma trials Research Report on Non-small Cell Carcinoma

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Combining ICI With SBRT or HypoFrx-RT for ES NSCLC
Stereotactic body radiotherapy, Hypofractionated radiotherapy, Durvalumab - Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Phase 1 / Phase 2UnknownAlexander Chi832023-10-092023-10-03
A Study of Vobramitamab Duocarmazine in Participants With Metastatic Castration Resistant Prostate Cancer and Other Solid Tumors
vobramitamab duocarmazine 2.0 mg (Arm A), vobramitamab duocarmazine 2.7 mg (Arm B), vobramitamab duocarmazine - Castration-Resistant Prostatic Cancer, Androgen-Independent Prostatic Cancer
Phase 2TerminatedMacroGenics1922023-06-132026-02-09
A Study of Targeted Radiation Therapy in People With Non-Small Cell Lung Cancer (NSCLC)
L-SABR, Anti-PD-(L)1 based immunotherapy, Platinum based chemotherapy - Non Small Cell Lung Cancer, Non Small Cell Lung Cancer Metastatic
Phase 2RecruitingMemorial Sloan Kettering Cancer Center682022-12-092026-05-07
Ramucirumab, Atezolizumab and N-803 After Progression on Any Immune Checkpoint Blocker in NSCLC
Ramucirumab, Atezolizumab, N-803 - Non-small Cell Lung Cancer, Non-small Cell Carcinoma
Phase 2WithdrawnWashington University School of Medicine2021-10-312021-11-05
Safety and Efficacy of Zimberelimab (AB122) in Combination With Domvanalimab (AB154) and Etrumadenant (AB928) in Patients With Previously Treated Non-Small Cell Lung Cancer
Zimberelimab, Domvanalimab, Etrumadenant - Non Small Cell Lung Cancer, Non-small Cell Carcinoma
Phase 2Active not recruitingWashington University School of Medicine302021-08-042026-11-09
Durvalumab Followed by Chemoradiation and Consolidation Durvalumab for Stage III Non-small Cell Lung Cancer
Induction Durvalumab, Chemotherapy, Radiation - Lung Cancer, Non-small Cell Carcinoma
Phase 2TerminatedRachel Sanborn102020-06-182024-12-20
Intrapleural Docetaxel Administration Using Medical Pleuroscopy in Malignant Effusion With Lung Cancer
intrapleural docetaxel administration - Pleural Effusion, Malignant, Non-small Cell Carcinoma
Phase 2CompletedAsan Medical Center42016-07-262019-03-08
Vaccine Treatment for Advanced Non-Small Cell Lung Cancer
Drug: Hyperacute Lung Cancer Cell Vaccine - Non-small Cell Carcinoma, Adenocarcinoma of Lung
Phase 1 / Phase 2CompletedNewLink Genetics Corporation542003-11-012020-05-28

Narrower conditions

Carcinoma, Non-Small-Cell Lung (6)  ·  Lung Neoplasms (2)  ·  Adenocarcinoma of Lung (1)  ·  Anus Neoplasms (1)  ·  Carcinoma, Large Cell (1)  ·  Carcinoma, Small Cell (1)  ·  Carcinoma, Squamous Cell (1)  ·  Melanoma (1)  ·  Pleural Effusion, Malignant (1)  ·  Prostatic Neoplasms, Castration-Resistant (1)  ·  Small Cell Lung Carcinoma (1)  ·  Squamous Cell Carcinoma of Head and Neck (1)

Broader conditions

Neoplasms (8)  ·  Neoplasms by Site (8)  ·  Respiratory Tract Diseases (8)  ·  Respiratory Tract Neoplasms (8)  ·  Thoracic Neoplasms (8)  ·  Lung Diseases (7)  ·  Bronchial Neoplasms (6)  ·  Carcinoma, Bronchogenic (6)  ·  Lung Neoplasms (5)  ·  Carcinoma (2)  ·  Neoplasms by Histologic Type (2)  ·  Neoplasms, Glandular and Epithelial (2)  ·  Adenocarcinoma (1)  ·  Anus Diseases (1)  ·  Carcinoma, Squamous Cell (1)

Interventions

durvalumab (2)  ·  ALT-803 (1)  ·  Carboplatin (1)  ·  Cisplatin (1)  ·  Drug Therapy (1)  ·  Etoposide (1)  ·  Pemetrexed (1)  ·  Platinum Compounds (1)  ·  Radiation (1)  ·  Radiation Dose Hypofractionation (1)  ·  Radiosurgery (1)  ·  Ramucirumab (1)  ·  Standard of Care (1)  ·  abiraterone (1)  ·  atezolizumab (1)

Sponsors

Washington University School of Medicine (2)  ·  Alexander Chi (1)  ·  Asan Medical Center (1)  ·  MacroGenics (1)  ·  Memorial Sloan Kettering Cancer Center (1)  ·  NewLink Genetics Corporation (1)  ·  Rachel Sanborn (1)

Countries

United States (5)  ·  South Korea (2)  ·  Australia (1)  ·  Belgium (1)  ·  China (1)  ·  France (1)  ·  Italy (1)  ·  Poland (1)  ·  Spain (1)  ·  United Kingdom (1)

Top investigators

Daniel Morgensztern, M.D. (2)  ·  Alexander Chi, MD (1)  ·  Arun Rajan, M.D. (1)  ·  Liudmila Schafer, M.D. (1)  ·  Paul Romesser, MD (1)  ·  Rachel Sanborn, MD (1)

Results publications

PMID 40898159